Profile
ACHL NVO VRTX REGN SGEN ARGX
Company Name Achilles Therapeutics plc Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $40.32M $459.47B $102.31B $75.85B $43.15B $37.66B
Employees 0.20K 71.88K 5.40K 14.17K 3.26K 1.15K
CEO Dr. Iraj Ali Ph.D. Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Ratings
ACHL NVO VRTX REGN SGEN ARGX
Quant Rating Score 2 3 3 4 3 1
Quant Rating Sell Neutral Neutral Buy Neutral Strong Sell
Trading
ACHL NVO VRTX REGN SGEN ARGX
Last Close $0.9811 $85 $397.27 $701.85 $228.74 $623.82
High 52 $1.57 $146.91 $516.74 $1201.76 $228.74 $638.33
Low 52 $0.7 $85 $392.81 $701.85 $228.74 $356.01
Price vs. 52 Week High -37.51 % -42.14 % -23.12 % -41.6 % 0 % -2.27 %
Price vs. 52 Week Low 40.16 % 0 % 1.14 % 0 % 0 % 75.23 %
Total Return
ACHL NVO VRTX REGN SGEN ARGX
1 Month Return -7.44 % -19.09 % -11.91 % -4.9 % 0 % 2.95 %
3 Month Return -5.66 % -33.34 % -14.55 % -38.7 % 0 % 17.04 %
6 Month Return 14.88 % -40.12 % -15.24 % -33.36 % 0 % 58.14 %
9 Month Return -22.54 % -34.08 % -4.5 % -27.48 % 0 % 54.84 %
YTD Return 10.36 % -17.83 % -2.36 % -20.09 % 0 % 63.98 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACHL NVO VRTX REGN SGEN ARGX
Dividend Yield Percentage (TTM) - 1.68 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -59.82 % 1.25 % -2.62 % 4.88 % -2.27 % -2.22 %
Dividend Per Share (TTM) - 9.9 % - - - -
Payout Ratio (TTM) - 46.6 % - - - -
Growth
ACHL NVO VRTX REGN SGEN ARGX
Asset Growth -26.73 % 30.35 % 25.23 % 13.23 % -1.21 % 44.93 %
Gross Profit Growth -28.3 % 32.32 % 9.64 % 6.49 % 22.93 % 190.7 %
Revenue Growth - 31.26 % 10.51 % 7.76 % 24.65 % 198.56 %
Revenue 3 Year - 90.03 % 60.36 % 55.67 % 91.56 % 2071.96 %
Revenue 5 Year - 123.63 % 219.55 % 110.3 % 215.48 % 3041.46 %
Revenue 10 Year - 65.69 % 610.45 % 549.62 % 494.04 % 9009.53 %
EBIT Growth 3.99 % 37.11 % 0 % -14.6 % 10.13 % 40.94 %
Net Income Growth 2.12 % 50.71 % 8.96 % -8.87 % 9.51 % 58.42 %
Net Income 3 Yeari Growth Per Share -113.25 % 106.26 % 34.59 % 13.48 % -763.59 % 64.01 %
Net Income 5 Yeari Growth Per Share 86.28 % 133.27 % 70.33 % 74.02 % -276.93 % -143.65 %
Net Income 10 Yeari Growth Per Share 86.28 % 98.1 % 809.6 % 871.12 % -624.16 % -857 %
Operating Income Growth 3.99 % 37.11 % 0 % -14.6 % 10.13 % 40.94 %
Operating Cash Flow Growth (CFG) 18.62 % 38.06 % -14.35 % -8.39 % 9.07 % 51.28 %
Operating 3 Year CFG -94.98 % 117.73 % 9.63 % 76.95 % -147.99 % 21.71 %
Operating 5 Year CFG -8546.04 % 162.84 % 174.78 % 125.17 % -195.86 % -329.63 %
Operating 10 Year CFG -8546.04 % 150.28 % 6084.35 % 713.56 % -2622.09 % -1280.2 %
EPS Growth 4.4 % 51.88 % 8.33 % -8.54 % 10.81 % 60.46 %
EPS Diluted Growth 4.4 % 52.37 % 8.35 % -9.03 % 10.81 % 60.46 %
Book Value Per Share -29.25 % 28.67 % 25.58 % 15.03 % -9.83 % 38.53 %
Share Holder 3 Year Equity Growth Per Share -23.6 % 74.77 % 104.06 % 137.56 % 33.72 % 93.75 %
Share Holder 5 Year Equity Growth Per Share -84.77 % 121.34 % 291.14 % 219.1 % 220.81 % 318.81 %
Share Holder 10 Year Equity Growth Per Share -84.77 % 49.24 % 1030.79 % 1286.9 % 691.19 % 3654.06 %
Dividend Per Share Growth - 26.56 % - - - -
Dividend 3 Year Growth Per Share - 63.98 % - - - -
Dividend 5 Year Growth Per Share - 79.57 % - - - -
Dividend 10 Year Growth Per Share - 94.94 % - - - -
Debt Growth -46.19 % 4.74 % 44.1 % 0.06 % -23.28 % 60.95 %
Free Cash Flow Growth 26.1 % 9.17 % -16.47 % -17.11 % 3.67 % 51.98 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
ACHL NVO VRTX REGN SGEN ARGX
Gross Profit Margin TTM - 84.66 % 86.1 % 84.42 % 72.37 % 86.82 %
Return on Assets TTM -54.64 % 23.83 % -2.16 % 12.43 % -11.76 % -2.13 %
Return on Equity TTM -54.57 % 86.4 % -2.88 % 16.85 % -16.53 % -2.75 %
Return on Capital Employed TTM -69.28 % 62.74 % -1.72 % 11.85 % -16.87 % -8.98 %
Net Income Per EBT TTM 100.74 % 79.43 % -184.82 % 93.66 % 100.55 % 167.72 %
EBT Per Ebit TTM 92.18 % 100.52 % -82.68 % 124.1 % 94.01 % 15.76 %
EBIT Per Revenue TTM - 43.84 % -2.96 % 28.92 % -36.09 % -17.08 %
Cash Flow To Debt Ratio TTM - 207.5 % - 214.08 % -185.98 % -
Receivables Turnover TTM - 3.89 6.06 2.27 1.98 3.45
Payables Turnover TTM 0.83 1.72 3.73 4.34 1.54 1.06
Inventory Turnover TTM - 1.09 1.37 0.71 0.65 0.91
Fixed Asset Turnover TTM - 225.8 % 422.11 % 311.93 % 256.83 % 6116.64 %
Asset Turnover TTM - 68.08 % 47.71 % 36.98 % 34.46 % 47.09 %
Operating Cash Flow Per Share TTM -1.19 26.54 -3.27 39.29 -1.12 -2.42
Free Cash Flow Per Share TTM -0.78 15.14 -4.51 31.25 -1.62 -3.52
Cash Per Share TTM 212.86 % 1681.33 % 2528.88 % 9062.44 % 657.5 % 5163.05 %
Operating Cash Flow Sales Ratio TTM - 43.69 % -7.94 % 30.67 % -16.85 % -6.44 %
Free Cash Flow Operating Cash Flow Ratio TTM 65.62 % 57.03 % 138.12 % 79.52 % 144.14 % 145.12 %
Cash Flow Coverage Ratios TTM - 207.5 % - 214.08 % -185.98 % -
Price To Free Cash Flows Ratio TTM -1.28 38.84 -87.91 22.46 -141.85 -178.29
Price To Operating Cash Flows Ratio TTM -0.83 22.2 -121.64 17.86 -203.89 -257.55
Price Cash Flow Ratio TTM -0.83 22.2 -121.64 17.86 -203.89 -257.55
Income Statement (TTM)
ACHL NVO VRTX REGN SGEN ARGX
Revenue $0B $232.26B $9.87B $13.12B $1.96B $1.23B
Gross Profit $-0B $196.5B $8.61B $11.3B $1.55B $1.11B
Gross Profit Ratio 0% 84.6% 87.21% 86.16% 79.1% 90.39%
EBITDA $-0.07B $114.63B $4.61B $4.69B $-0.62B $-0.22B
Net Income $-0.07B $83.68B $3.62B $3.95B $-0.61B $-0.3B
EPS Diluted -1.74 18.62 13.89 34.77 -3.3 -5.16
Balance Sheet (MRQ)
ACHL NVO VRTX REGN SGEN ARGX
Long Term Debt $0B $20.53B $1.45B $2.7B $0.04B $0.02B
Total Liabilities $0.02B $207.93B $5.15B $7.11B $0.87B $0.44B
Total Equity $0.14B $106.56B $17.58B $25.97B $2.8B $4.1B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $1.18B
Total Debt $0B $27.01B $0.81B $2.7B $0.04B $0.02B
Total Assets $0.16B $314.49B $22.73B $33.08B $3.67B $4.54B
Cash Flow Statement (TTM)
ACHL NVO VRTX REGN SGEN ARGX
Net Income $-0.07B $83.68B $3.62B $3.95B $-0.61B $-0.43B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $-0.08B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.05B $108.91B $3.54B $4.59B $-0.45B $-0.42B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.04B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 3.39
ABCL AbCellera Biologics Inc. 2.85
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.7
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.85
ABSI Absci Corporation 2.99
ABUS Arbutus Biopharma Corporation 3.21
ABVC ABVC BioPharma, Inc. 0.524
ABVX Abivax SA American Depositary Shares 7.65
ACAD ACADIA Pharmaceuticals Inc. 16.87
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.91
ACGN Aceragen, Inc. 0.3849
ACHV Achieve Life Sciences, Inc. 3.69
ACIU AC Immune SA 2.68
ACLX Arcellx, Inc. 75.54
ACRV Acrivon Therapeutics, Inc. Common Stock 6.71
ACST Acasti Pharma Inc. 3.37
ACXP Acurx Pharmaceuticals, Inc. 0.825
ETFs With Exposure to ACHL
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0.01 132.73
BIB ProShares Ultra Nasdaq Biotechnology 0 51.41
IBBQ Invesco Nasdaq Biotechnology ETF 0 21.6
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 6.30625
Unlock